All stock lists
Integra Lifesciences Holdings Corp (NASDAQ:IART)
US · Delayed Price · Currency is USD
Healthcare · Medical - Devices
12.10+0.19 (+1.60%)
Insider Score
––Not scored
IART Insider Score
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
IART Stock Insider Trading Activity
IART stock’s insider trading shows no open-market insider trades by company insiders over the last 6 months.
Not enough price history.
Insider Trading Activity (Form 4 Filings)
An insider trade occurs when an individual that has non-public information about a company buys or sells shares of that company’s stock. Examples of insiders include a company’s executive officers (CEO, CFO, COO), its board of directors, and its major shareholders. Insiders are required to submit their trading activity to the SEC through Form 4 filings.
| Insider | Action | Shares | Avg Cost | Total | Δ Holdings | Held After | Date | Grade | Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Veillon-Berteloot Chantal Other | Tax withheld | 1,455 | $16.62 | $24.18K | 6.5% | 20,772 | Sep 1, 2026 | — | Form 4 |
| Knight Lea Daniels CFO | Tax withheld | 5,226 | $18.05 | $94.33K | 10.4% | 45,263 | Jul 3, 2026 | — | Form 4 |
| Mosebrook Jeffrey Other | Tax withheld | 937 | $17.89 | $16.76K | 2.6% | 34,516 | Jul 1, 2026 | — | Form 4 |
| BRADLEY KEITH Director | Tax withheld | 882 | $13.92 | $12.28K | 1.0% | 88,254 | May 9, 2026 | — | Form 4 |
| HILL BARBARA B Director | Award | 6,638 | — | — | 5.2% | 133,491 | May 7, 2026 | — | Form 4 |
| HILL BARBARA B Director | Award | 17,700 | — | — | 13.3% | 151,191 | May 7, 2026 | — | Form 4 |
| Singh Harvinder Other | Tax withheld | 861 | $9.61 | $8.27K | 3.8% | 21,690 | Mar 11, 2026 | — | Form 4 |
| Mosebrook Jeffrey Other | Tax withheld | 806 | $9.61 | $7.75K | 2.2% | 35,453 | Mar 11, 2026 | — | Form 4 |
| Knight Lea Daniels CFO | Tax withheld | 8,089 | $9.61 | $77.74K | 13.8% | 50,489 | Mar 11, 2026 | — | Form 4 |
| DAVIS ROBERT T. JR. Other | Tax withheld | 8,487 | $9.61 | $81.56K | 11.3% | 66,387 | Mar 11, 2026 | — | Form 4 |
| Veillon-Berteloot Chantal Other | Tax withheld | 5,420 | $9.61 | $52.09K | 19.6% | 22,227 | Mar 11, 2026 | — | Form 4 |
| McBreen Michael J. Other | Tax withheld | 7,247 | $9.61 | $69.64K | 10.7% | 60,743 | Mar 11, 2026 | — | Form 4 |
| Singh Harvinder Other | Option exercise | 18,922 | — | — | 87.2% | 40,612 | Mar 11, 2026 | — | Form 4 |
| Singh Harvinder Other | Tax withheld | 5,190 | $9.61 | $49.88K | 12.8% | 35,422 | Mar 11, 2026 | — | Form 4 |
| DAVIS ROBERT T. JR. Other | Tax withheld | 687 | $9.55 | $6.56K | 0.9% | 74,874 | Mar 10, 2026 | — | Form 4 |
| Singh Harvinder Other | Option exercise | 1,216 | — | — | 5.5% | 23,152 | Mar 10, 2026 | — | Form 4 |
| McBreen Michael J. Other | Tax withheld | 2,354 | $9.55 | $22.48K | 3.3% | 67,990 | Mar 10, 2026 | — | Form 4 |
| Mosebrook Jeffrey Other | Tax withheld | 341 | $9.55 | $3.26K | 0.9% | 36,259 | Mar 10, 2026 | — | Form 4 |
| Singh Harvinder Other | Tax withheld | 601 | $9.55 | $5.74K | 2.6% | 22,551 | Mar 10, 2026 | — | Form 4 |
| Poul Mojdeh CEO | Tax withheld | 542 | $13.13 | $7.12K | 100% | 0 | Jan 6, 2026 | — | Form 4 |
| Poul Mojdeh CEO | Tax withheld | 848 | $13.13 | $11.13K | 61.0% | 542 | Jan 6, 2026 | — | Form 4 |
What these mean— the action is the SEC’s own Form 4 transaction code. Only a buy or a sell is an open-market trade; the rest are transfers, awards and exercises, which is why they carry no price.
- Award (A) — Grant or award from the company, not a purchase
- Tax withheld (F) — Shares withheld to pay tax or an exercise price
- Option exercise (M) — Exercise or conversion of an exempt derivative
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.